Epidemiology of left ventricular hypertrophy
such as gender, age, increased body mass index, angiotensin II, aldosterone and parathyroid hormone play Left ventricular (LV ) hypertrophy is a frequent finding a modulating role in the extent of LV hypertrophy. It in a population with established systemic hypertension has been documented beyond any doubt that LV with an echocardiographically determined prevalance hypertrophy does regress after starting antihypertensof up to 48% depending on the definition of the upper ive therapy. Several studies now provide indirect evidnormal limit of LV mass. LV hypertrophy is prima-ence for an improved prognosis after regression of LV rily a compensatory mechanism in response to the hypertrophy. Data from the Framingham study at first increased workload imposed on the heart in hypertens-showed that cardiovascular mortality was reduced ive subjects. However, LV hypertrophy represents a when LV hypertrophy was reduced [4] . major risk factor with respect to cardiovascular morbidity and mortality in primary and secondary arterial hypertension and in end-stage renal disease ( ESRD)
Geometry of LV hypertrophy [1] [2] [3] . The increased risk is attributable to several sequelae of LV hypertrophy such as an impaired dia-LV hypertrophy is defined by arbitrary criteria, such stolic filling of the LV cavity, one of the earliest as posterior wall thickness exceeding 1.1 cm, or better negative consequences of hypertensive heart disease, LV mass index exceeding 131 g/m2 in men (110 g/m2 or an impaired systolic function which both ultimately in women). LV hypertrophy represents a remodelling lead to clinical signs of congestive heart failure. The process of the heart architecture to normalize wall increased risk is also related to vascular changes in stress. The particular pattern of hypertrophy is dependcoronary arteries leading to a decreased coronary ent on the type of load that is imposed on the LV. blood flow (in addition to the increased risk for
Increased afterload leads to an increase in end-systolic coronary atherosclerosis). Last but not least, increased and peak wall stress and the addition of sarcomers in ectopic ventricular activity found in patients with LV parallel to an increase in LV wall thickness at the hypertrophy increases the risk of sudden cardiac death.
expense of chamber volume thus increasing relative wall thickness [5] . This pattern has been termed 'concentric remodelling' and if LV mass is above the upper Correspondence and offprint requests to: Prof. Dr Roland normal limit 'concentric hypertrophy'. However, some E. Schmieder, Medizinische Klinik IV/Nephrologie, Universität hypertensive patients, especially those with concomit- tant volume overload states such as obesity or patent arterio-venous fistula, develop 'eccentric hypertrophy', being characteristic and frequent in haemodialysis.
This pattern of LV hypertrophy is related to chronic characterized by an increased left ventricular mass but normal relative wall thickness [6 ] . In contrast to volume and flow overload, that is associated with three factors: presence of an arterio-venous shunt, sodium 'physiologic hypertrophy' as encountered in athletes, pathologic forms of LV hypertrophy are accompanied and water retention, and anaemia. Since a dilated LV is a poor prognostic marker in dialysis patients, Foley by interstitial fibrosis. Due to decreased relaxation in early diastole, an impaired LV filling is the diagnostic et al. investigated 433 patients on ESRD therapy [9] .
They found in patients with normal LV diameter that criteria that favours the diagnosis 'pathologic' LV hypertrophy (decreased E:A ratio, i.e. the ratio of early high LV mass and mass:volume ratios were associated with an adverse prognosis, similar to observations in to late diastolic filling), in contrast to a normal or even supranormal LV diastolic filling in 'physiologic' the general population and in patients with essential hypertension. In contrast, in patients with increased LV hypertrophy.
LV volume an elevated LV mass had no independent effect on cardiovascular prognosis. Of the echocardio-
LV hypertrophy in ESRD
graphic variables tested, LV cavity volume (especially in excess of 120 ml/m2) had the worst prognosis. These patients that have an inadequate low compensatory Among ESRD patients, the prevalance of LV hypertrophy with up to 70% and the degree of LV hyper-LV hypertrophy for yet unknown reasons are at very high risk to develop congestive heart failure with high trophy in relation to a similar afterload is even higher than among patients with essential hypertension. LV mortality rate for ESRD patients.
Based on these findings Foley et al. developed a hypertrophy in ESRD patients is predictive of cardiovascular mortality independently of other well-known geometric classification for patients with ESRD. (i)
Normal LV volume and normal LV mass (<120 g/mO); risk factors [2, 3] with a 5-year survival rate more than two times higher in patients with normal LV mass as (ii) LV volume 90-120 ml/m2 irrespective of LV mass;
(iii) Normal LV volumen with LV mass >120 g/m2; opposed to patients with increased LV mass [7] . In addition to the above mentioned risk factors, further (iv) LV volume >120 ml/m2 irrespective of LV mass.
Compared with Group I patients, the adjusted relative risk factors for the development of LV hypertrophy, such as anaemia, a patent arterio-venous fistula, a risk of death after 2 years on dialysis rose stepwise from 2.5 in Group II to 3.29 in Group III and 17.4 in disturbed elasticity of central arteries with elevated impedance, hypervolaemia, and hyperreninaemia are Group IV. The proposed classification appears to be superior to one based merely on LV mass index alone, encountered in ESRD patients. With duration of dialysis treatment LV mass increases progressively-even since patients with LV hypertrophy and a dilated left ventricle, i.e. low LV mass:volume ratio would be in normotensive patients-and usually ESRD patients present with LV hypertrophy of mostly eccentric pat-classified corresponding to their clinical status, namely incipient or overt congestive heart failure. Clearly in tern. Compared with controls LV mass is higher in normotensive ESRD patients, but LV mass:volume patients with a dilated LV and most likely depressed cardiac pump function impaired LV function is more ratio remains similar since LV volume is also elevated. However, in hypertensive ESRD patients, the LV predictive for cardiovascular morbidity and mortality than LV mass per se. mass:volume ratio is usually decreased compared to hypertensive non-uraemic patients, i.e. the increase in LV mass:volume ratio is less than expected for a given systolic pressure. Thus, the LV hypertrophy is inad-
Therapy of LV hypertrophy in ESRD
equate. This abnormal adaptation of the LV is related with at least two factors. The first is arterial hypertension itself; in ESRD patients the deviation of the LV The therapeutic options in patients with secondary hypertension and in ESRD patients should be chosen mass:volume ratio from predicted values for normal controls is greater, the higher the blood pressure. according to the prevailing values of theses parameters.
In ESRD patients with elevated LV volume the main Second is hyperparathyroidism; among the many substances that have been incriminated to be responsible therapeutic option should be to reduce hypervolaemia, to counteract LV remodelling by blocking the action for the 'cardiopressor' effect in uraemia, parathormone plays the most intriguing role [8] .
of angiotensin II and sympathetic nervous system, to correct anaemia and to treat hyperparathyroidism [8] .
In ESRD patients with increased LV mass index in LV geometry in ESRD face of a normal or reduced LV volume, antihypertensive therapy including ACE inhibitors or AT 1 -receptor antagonists should be favoured, since first according The clinical importance of LV hypertrophy in ESRD patients seems predominantly determined by the cor-to a metaanalysis of only randomized double-blind trials the greatest benefit with regard to reducing LV responding LV geometry. With the exception of some studies most authors report an increase in the internal mass was seen with angiotensin II blocking drugs [10] and second blocking the effects of angiotensin II in dimensions of LV cavities in parallel to an increase in LV wall thickness, i.e. eccentric LV hypertrophy, as patients with dilated LV has clearly positive effects features and their serial changes in subjects with left ventricular according to several prospective studies in congestive hypertrophy. Circulation 1994; 90: 1786-1793 heart failure. 
